Host Brian McDonough talks with Dr. Joel Nitzkin, preventive medicine physician and senior fellow in tobacco policy for the R Street Institute. The two discuss their respective priorities for reducing tobacco-attributable illnesses and death.
Tobacco Cessation: Clinical and Public Health Perspectives on Breaking the Habit
Dr. Joel Nitzkin explores options for ending people's dependency on cigarettes.
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Host Brian McDonough talks with Dr. Joel Nitzkin, preventive medicine physician and senior fellow in tobacco policy for the R Street Institute. The two discuss their respective priorities for reducing tobacco-attributable illnesses and death.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE Broadcast Replay
Love Story: Lipid Education for Women’s Heart Health
0.50 credits
<p>Love Story: Lipid Education for Women’s Heart Health</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
MinuteCE®
Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy
1.25 credits
<p>Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy</p>
MinuteCE®
What do we know now that could have changed the history of CETP inhibition?: genetics and biology
0.50 credits
<p>What do we know now that could have changed the history of CETP inhibition?: genetics and biology </p>
CME/CE
Impact of Barostim on Heart Failure Hospitalization
<p>Impact of Barostim on Heart Failure Hospitalization</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?